There is little evidence to support the argument that vaccine development has suddenly become too complex for public research institutes, as is made out. It would be cheaper for the Gates Foundation to invest in vaccine research by academic and public research institutions. The resulting vaccines would be publicly available, regional and national manufacturers could produce them cheaply, uptake would increase, and the poor children of the world would benefit.

We declare that we have no conflict of interest.

Amit Kumar, *Jacob Puliyel
Puliyel@vsnl.com
Department of Pediatrics, St Stephens Hospital, Tis Hazari, Delhi 110054, India


Response from GAVI Alliance

Although we applaud the commitment of Amit Kumar and Jacob Puliyel to child immunisation, many of their contentions are based on a flawed understanding of GAVI’s work. There is overwhelming evidence that immunisation is one of the most cost-effective public-health interventions a country can make. Simply put, the vaccines funded by GAVI are saving lives. GAVI, through its partners, has immunised more than 115 million children, preventing an estimated 1.7 million deaths. GAVI works with its partners, including industrialised and developing countries, vaccine makers, WHO, UNICEF, and others, to ensure that the vaccines adopted by each country are affordable and appropriate for the unique needs of each country.

Sustaining and building on the gains of developing countries continues to be a priority for GAVI, and we are working with countries to help them support the vaccines they have introduced. GAVI provides countries with vaccines over long periods (5–15 years) to enable ministers of health to determine priorities and affordability and to make the kind of decisions about public health trade-offs noted by Kumar and Puliyel.

Vaccine research, although crucially important, is not a substitute for a multifaceted approach to child health and immunisation. Several complementary investments are needed to ensure the appropriate vaccines are developed, manufactured, and accessible to citizens of the developing world. GAVI and other organisations are supporting researchers and vaccine makers in their efforts.

A reinvigorated global movement is needed to increase access to immunisation and to ensure that we reach the Millennium Development Goals. We are well on our way to making this happen.

I declare that I have no conflict of interest.

Jean-Pierre Le Calvez
jplecalvez@gavialliance.org
GAVI Alliance, c/o UNICEF, Palais des Nations, CH-1211 Geneva 10, Switzerland

Adjudication of serious heart failure in patients from PROactive

There has been much discussion of the increased incidence of investigator-reported heart failure with pioglitazone in the PROactive study versus the drug’s potential benefit in preventing macrovascular complications in type 2 diabetes. Because heart failure events were reported as adverse events and

The printed journal includes an image merely for illustration